glp 1 novo Ozempic is first GLP-1 drug FDA-approved for kidney disease Novo Nordisk's oral GLP-1 drug
Description
Caution is advised, with dose reduction recommended in some cases, when they are combined with a sulphonylurea or insulin as the risk of hypoglycemia is higher
Nunn E, Jaiswal N, Gavin M, et al
Weight regain is very common after stopping a GLP-1on average, up to two-thirds of the lost weight is regained within one year
That's standard for a 50-state telehealth MSO - it's not a gap in the system, it's how responsible multi-state telehealth networks are designed to function
